No Data
Investors Might Be Losing Patience for Crinetics Pharmaceuticals' (NASDAQ:CRNX) Increasing Losses, as Stock Sheds 5.6% Over the Past Week
LifeSci Capital Maintains Crinetics(CRNX.US) With Buy Rating, Maintains Target Price $77
Crinetics Pharmaceuticals: Strong Buy Recommendation Driven by Best-in-Class Efficacy and Solid Financial Position
State Street Corp's Strategic Acquisition in Crinetics Pharmaceuticals
Crinetics Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 12, 2024
JonesTrading Maintains Crinetics(CRNX.US) With Buy Rating, Raises Target Price to $71
No Data
No Data
